FDA Accepts Supplement for TUXARIN ER by MAINPOINTE
The FDA has accepted a supplemental application for TUXARIN ER, which contains chlorpheniramine maleate and codeine phosphate.
Asset / Drug
Drug and asset intelligence for MAINPOINTE with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.